← All themes Genomics & Gene Editing

Gene Therapy

Gene therapy delivers a working copy of a gene, or a correction to a faulty one, usually once and for life. Manufacturing the delivery vector is often harder than designing the therapy.

131 stocks

#	Name	Funds holding	Growth	Growth %	Fund value
26	ATHX 26 DELISTED Athersys, Inc. Common Stock ATHX	125	-5	-4%	$34.4M
27	27 Ocugen OCGN $274M	122	0	0%	$279M
28	RUBY 28 DELISTED Rubius Therapeutics, Inc RUBY	117	+9	+8%	$494M
29	29 Sana Biotechnology SANA $733M	117	+12	+11%	$986M
30	30 Lineage Cell Therapeutics LCTX $248M	110	-14	-11%	$112M
31	31 Passage Bio PASG $11.6M	108	+9	+9%	$133M
32	32 Caribou Biosciences CRBU $48.6M	104	+11	+12%	$313M
33	33 MeiraGTx Holdings MGTX $937M	103	+4	+4%	$406M
34	34 Cartesian Therapeutics RNAC $198M	102	-4	-4%	$71.9M
35	TCRR 35 DELISTED TCR2 Therapeutics Inc. Common Stock TCRR	94	-28	-23%	$74.8M
36	36 DELISTED Adverum Biotechnologies ADVM	92	-6	-6%	$85.9M
37	ATNX 37 DELISTED Athenex, Inc. Common Stock ATNX	91	-12	-12%	$37.3M
38	38 Lakefront Biotherapeutics American Depositary Shares LKFT $1.97B	89	+7	+9%	$796M
39	39 DELISTED Generation Bio GBIO	88	0	0%	$416M
40	40 Adicet Bio ACET $47.4M	87	+6	+7%	$660M
41	41 DELISTED Carisma Therapeutics CARM	84	-9	-10%	$29.5M
42	42 Nkarta NKTX $138M	84	-8	-9%	$287M
43	43 Mustang Bio MBIO $2.93M	81	-2	-2%	$25.3M
44	44 Neurogene NGNE $482M	81	+1	+1%	$49.7M
45	45 ProKidney PROK $305M	81	-9	-10%	$236M
46	ADAP 46 DELISTED Adaptimmune Therapeutics ADAP	80	-5	-6%	$229M
47	47 4D Molecular Therapeutics FDMT $706M	80	+3	+4%	$395M
48	48 Fortress Biotech FBIO $63.7M	79	-3	-4%	$48.4M
49	49 Lyell Immunopharma LYEL $199M	79	+2	+3%	$503M
50	50 Instil Bio TIL $43.1M	78	+1	+1%	$1.27B